10-Q: Niagen Bioscience Reports Strong Q2 Profit, Revenue Surge

Niagen Bioscience, Inc. announced a significant turnaround in its second quarter, reporting substantial net income and robust revenue growth driven by its consumer products and ingredients segments.

Summary

• Niagen Bioscience reported net sales of $31.1 million for the three months ended June 30, 2025, a 37% increase from $22.7 million in the same period of 2024.
• Gross profit for the quarter increased by 48% to $20.2 million, up from $13.7 million in Q2 2024.
• The company achieved a net income of $3.6 million for the three months ended June 30, 2025, a significant improvement from a net loss of $15,000 in Q2 2024.
• For the six months ended June 30, 2025, net sales reached $61.6 million, a 37% increase from $44.9 million in the prior year period.
• Year-to-date gross profit rose by 46% to $39.6 million, compared to $27.1 million in the first half of 2024.
• Net income for the six months ended June 30, 2025, was $8.7 million, a substantial improvement from a net loss of $507,000 in the first half of 2024.
• Basic earnings per share were $0.05 for the quarter and $0.11 year-to-date, compared to a basic loss per share of $0.00 and $(0.01) respectively in the prior year periods.
• The Consumer Products segment saw sales increase by 22% for the quarter and 23% year-to-date, primarily driven by e-commerce channel performance.
• The Ingredients segment experienced a 131% increase in sales for the quarter and 114% year-to-date, boosted by higher food-grade Niagen sales and the launch of pharmaceutical-grade Niagen.
• Operating activities provided $9.1 million in cash for the six months ended June 30, 2025, a significant increase from $31,000 in the prior year period.
• The company settled the California Action legal proceeding with Elysium Health, LLC, receiving the final $1.325 million installment of a $2.65 million settlement payment on March 28, 2025, which was recorded as a recovery of credit losses.
• A new Sales Agreement with W. R. Grace & Co.-Conn. (Grace) was executed on July 25, 2025, effective April 1, 2025, making Grace the exclusive supplier of Nicotinamide-beta-Riboside Chloride (NRCL) through April 30, 2029, with a purchase commitment of approximately $32.6 million through July 31, 2026.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround with significant revenue growth, improved profitability, and positive operating cash flow. The resolution of one major legal dispute is a positive, and securing a key supply agreement is crucial. However, the ongoing patent litigation with a substantial potential liability and the inherent risks of single-source supply temper the overall sentiment, preventing a perfect score.

Positives

• Achieved significant net income of $3.6 million for the quarter and $8.7 million year-to-date, reversing prior-year losses.
• Reported strong revenue growth of 37% for both the three and six months ended June 30, 2025, demonstrating increased market penetration and demand.
• Gross profit margins improved across all segments, reflecting enhanced operational efficiency and favorable product mix shifts.
• Generated positive cash flow from operating activities of $9.1 million for the six months, indicating improved financial health and self-sufficiency.
• Successfully resolved the California Action legal dispute with Elysium Health, LLC, receiving the full $2.65 million settlement payment.
• Secured a long-term exclusive supply agreement for Nicotinamide-beta-Riboside Chloride (NRCL) with W. R. Grace & Co.-Conn. through April 2029, ensuring critical raw material availability.
• E-commerce channel performance significantly contributed to Consumer Products segment growth, indicating effective digital marketing and customer acquisition strategies.
• Successful launch and initial sales contribution from pharmaceutical-grade Niagen, diversifying revenue streams within the Ingredients segment.

Negatives

• Sales to A.S. Watson Group experienced a temporary decline due to reduced replenishment order volumes, though stabilization is expected in the second half of 2025.
• General and administrative expenses increased by $1.6 million for the quarter and $1.4 million year-to-date, driven by higher employee-related expenses, share-based compensation, and professional/consulting fees.
• The company faces an ongoing patent infringement appeal in Delaware against Elysium Health, Inc., with a potential liability of approximately $10.4 million (including interest) if the appeal is unsuccessful, for which no accrual has been recorded.
• Reliance on a single supplier (W.R. Grace) for NRC creates supply chain concentration risk, despite the new exclusive agreement.
• The new supply agreement with Grace includes a significant purchase commitment of $32.6 million through July 31, 2026, which could impact working capital and inventory management.

Risks

• History of operating losses and potential need for additional financing if profitability is not sustained or for long-term strategic objectives.
• Interruptions or declines in business with major customers could materially harm financial results due to high customer concentration.
• Negative impacts from global, market, and economic conditions, including inflation, interest rates, and geopolitical issues.
• Future success is largely dependent on sales of the Tru Niagen product, making market acceptance critical.
• The success of consumer product and ingredient businesses is linked to the size and growth rate of the wellness industry market, which is subject to change.
• Effectiveness and efficiency of marketing efforts are crucial for future growth and profitability of the consumer product business.
• Competition from larger companies with greater financial and other resources.
• Operating results may fluctuate significantly due to various unpredictable factors, making future results difficult to predict.
• Inability to maintain or develop sales, marketing, and distribution capabilities, or arrangements with third parties, could harm the business.
• Potential negative impact from cyber security incidents or threats, including operational interruptions, data loss, and reputational harm.
• Reliance on a single supplier (W.R. Grace) for NRC and a limited number of third-party suppliers for raw materials poses supply chain risks.
• Unfavorable publicity or consumer perception of products could materially affect the business.
• Risk of material product liability claims or class action litigation, increasing costs and affecting reputation.
• Negative effects from international trade and importation issues due to reliance on foreign suppliers.
• Uncertainty in protecting intellectual property and proprietary technology through patents and other means.
• Patents and licenses may be subject to validity challenges, and patent applications may be rejected.
• Risk of claims of infringement or misappropriation of intellectual property rights of others, leading to substantial monetary damages or inability to develop products.
• Lack of control over prosecution and enforcement of patents licensed from third parties.
• Potential for damages from claims of wrongful use or disclosure of alleged trade secrets by employees or contractors.
• Changes in government regulation or practices relating to the pharmaceutical, dietary supplement, food, and cosmetic industry could affect compliance and demand.
• Compliance with stringent and changing global privacy and data security laws and regulations could result in additional costs and liabilities.
• Market price volatility of common stock due to various factors.
• No history of cash dividends, limiting return on investment to stock appreciation.
• Potential dilution from significant outstanding options, unvested restricted stock units, and market performance stock units.
• Limitations on the ability to use net operating loss (NOL) carryforwards and certain other tax attributes.
• Bylaws provide for Delaware Court of Chancery as exclusive forum for certain disputes, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Risk of securities class action litigation diverting management's attention.
• Failure to establish and maintain effective internal control over financial reporting could result in material misstatements.
• Limited operating history in China and uncertainties in developing successful channels there.
• Environmental, social, and governance (ESG) matters may impact business and reputation, potentially increasing costs.
• Changes in tax laws or regulations applied adversely to the company or its customers.

Future Outlook

Management anticipates that current unrestricted cash and cash equivalents, combined with cash generated from net sales, will be sufficient to meet financial obligations for at least the next twelve months and beyond. The company may seek additional capital within the next twelve months to fund projected operating plans beyond this period and/or to support longer-term strategic objectives. Sales trends with A.S. Watson are expected to stabilize in the second half of 2025. Research and development spending is expected to fluctuate based on project timing and scope, returning to more normalized levels after recent initiatives.

Management Comments

• Management assessed that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months from the issuance date of these Unaudited Condensed Consolidated Financial Statements.
• The company may, however, seek additional capital within the next twelve months, both to fund its projected operating plans after the next twelve months and/or to fund the Company's longer-term strategic objectives.
• We expect sales trends with A.S. Watson to stabilize in the second half of 2025.
• As expected, R&D spending has returned to more normalized levels following these initiatives. We continue to anticipate fluctuations in R&D investment based on the timing and scope of specific projects, clinical development activities, and internal resource allocation.

Industry Context

Niagen Bioscience operates within the rapidly growing healthy aging and wellness industry, specifically focusing on NAD+ precursors. The company's strong performance, particularly in its Ingredients segment with the launch of pharmaceutical-grade Niagen, aligns with the increasing demand for science-backed nutritional and medical solutions. The expansion into pharmaceutical-grade ingredients and partnerships with healthcare practitioners positions the company to capitalize on the evolving landscape of personalized health and preventative medicine, where NAD+ research is gaining significant traction. The industry is characterized by intense competition and evolving regulatory landscapes, which the company addresses through its patent portfolio and scientific research programs.

Comparison to Industry Standards

• The significant revenue growth of 37% for both the quarter and year-to-date periods suggests a strong market position and potentially outperforming many competitors in the dietary supplement and ingredient sectors, especially given the general economic climate.
• The shift from net losses to substantial net income ($8.7 million YTD) indicates a strong operational turnaround and improved profitability, which is a positive outlier compared to many smaller bioscience companies that often remain unprofitable for extended periods.
• The improvement in gross profit margins across all segments (e.g., Consumer Products improving by 200-300 basis points, Ingredients by 900-1000 basis points) demonstrates effective cost management and favorable product mix, potentially exceeding industry averages for efficiency.
• The successful resolution of the California Action legal dispute, resulting in a $2.65 million settlement payment received, is a positive outcome that reduces legal overhang, unlike many ongoing, unresolved litigations seen with comparable companies in the intellectual property-heavy biotech space.
• The securing of an exclusive supply agreement for NRCL with W.R. Grace & Co.-Conn. provides supply chain stability, a critical advantage in an industry often prone to raw material disruptions, although it introduces single-source dependency.
• The launch of pharmaceutical-grade Niagen and its contribution to revenue growth positions the company favorably against competitors focused solely on consumer-grade supplements, indicating a strategic move into higher-value, prescription-based markets, similar to how some nutraceutical companies seek pharmaceutical applications for their compounds.

Management Changes

Corporate Governance

Legal Proceedings

• **California Action (Elysium Health, LLC)**: The company settled this dispute, receiving a total of $2,650,000 in two equal installments ($1,325,000 each on December 27, 2024, and March 28, 2025). The judgment was fully satisfied on April 4, 2025.
• **Delaware Patent Infringement Action (Elysium Health, Inc.)**: The company is appealing a final judgment from October 28, 2024, which granted Elysium's motion for attorneys' fees and costs of $9.2 million, plus judgment interest. The company believes the court abused its discretion and has not recorded an accrual for this contingent liability, which could reach approximately $10.4 million if the appeal is unsuccessful. Oral argument has not yet been scheduled.
• **Contingencies (Licensor)**: A licensor claimed $1.6 million plus interest for sublicense fees in September 2019. The company believes it does not owe these fees and does not expect the ultimate resolution to be material to its financial results.

Related Party Transactions

• A.S. Watson Group ceased to be a related party on August 20, 2024, due to a change in common ownership. Sales to A.S. Watson Group (as a former related party) were $0 for the three and six months ended June 30, 2025, compared to $3.7 million and $6.7 million for the respective periods in 2024. No trade receivables were connected to related parties as of June 30, 2025, or December 31, 2024.

Stakeholder Impact

• **Shareholders**: Positive impact from significant net income and revenue growth, potentially leading to increased share value. However, potential dilution from future equity offerings and the ongoing legal liability in the Delaware patent case pose risks.
• **Employees**: Increased employee-related expenses and share-based compensation indicate continued investment in human capital. The amendment to the equity incentive plan provides more shares for compensation, potentially boosting morale and retention.
• **Customers**: Continued product development and secured supply of key ingredients (NRCL) ensure product availability and quality. The launch of pharmaceutical-grade Niagen expands offerings to healthcare practitioners.
• **Suppliers**: The new exclusive supply agreement with W. R. Grace & Co.-Conn. solidifies a key supplier relationship but also creates a significant purchase commitment for the company.
• **Creditors**: Improved cash flow from operations and a strong cash position enhance the company's ability to meet financial obligations, reducing credit risk.

Next Steps

• Monitor sales trends with A.S. Watson to ensure stabilization in the second half of 2025.
• Continue to evaluate the impact of ASU 2023-06, ASU 2023-09, ASU 2024-02, and ASU 2024-03 on consolidated financial statements and disclosures.
• Manage the $32.6 million inventory purchase commitment through July 31, 2026, under the new supply agreement with W. R. Grace & Co.-Conn.
• Engage in good faith efforts to execute a supplemental License Agreement with Grace for manufacturing NRCL.
• Continue to pursue the appeal of the $9.2 million attorneys' fees and costs judgment in the Delaware patent infringement action.
• Monitor guidance and communications from the IRS regarding the Employee Retention Tax Credit (ERTC) claim.

Key Dates

Recommendation

The company has demonstrated a remarkable financial turnaround, moving from net losses to substantial profitability and positive operating cash flow. The 37% revenue growth across both the quarter and year-to-date periods, coupled with improved gross profit margins, indicates strong operational execution and increasing market demand for its products, particularly in the high-growth NAD+ space. The successful resolution of the California legal action removes a significant overhang. While the ongoing Delaware patent appeal with a potential $10.4 million liability is a notable risk, the company's confidence in its appeal, combined with its robust financial performance and secured supply chain for a critical ingredient, suggests a strong growth trajectory. For a seasoned investor, the current positive momentum and strategic positioning outweigh the identified risks, making it an attractive investment opportunity.

Keywords

NAD+, Nicotinamide Riboside, Niagen, Tru Niagen, Dietary Supplements, Healthy Aging, Bioscience, Nutraceuticals, Pharmaceutical Ingredients, Consumer Health, SEC Filing, Quarterly Report, Financial Results